RecruitingPhase 2NCT05104736
Oncology
Thymoma and Thymic Carcinoma
Also known as thymic epithelial tumor, WHO type A-B3 thymoma, thymic carcinoma
Thymoma and thymic carcinoma are rare thymic epithelial tumours classified by WHO histological subtype (A, AB, B1, B2, B3 for thymomas, and C for thymic carcinoma), with markedly differing biology and prognosis across the spectrum. Thymomas
ORPHA:99870 ↗Prevalence 1.5–1.7 in 1,000,000Onset Adult (median age 50s for thymoma; 40s–50s for thymic carcinoma)Sporadic
19
studies recruiting now
as of 7 Sept 2026
89
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
7 Jan 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT06885697
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RecruitingPhase 2NCT07324629
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
RecruitingPhase 1NCT03295227
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
RecruitingPhase 2NCT06980077
Ivonescimab for the Treatment of Thymic Cancer
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 19 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Thymoma and Thymic Carcinoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
About Thymoma and Thymic Carcinoma
Thymoma and thymic carcinoma are rare thymic epithelial tumours classified by WHO histological subtype (A, AB, B1, B2, B3 for thymomas, and C for thymic carcinoma), with markedly differing biology and prognosis across the spectrum. Thymomas are characterised by their unique association with autoimmune disorders — most notably myasthenia gravis, which occurs in 30–50% of thymoma patients — as well as pure red cell aplasia and hypogammaglobulinaemia. Thymic carcinoma lacks these paraneoplastic associations but is typically more aggressive, with higher rates of distant metastasis and a paucity of effective second-line systemic therapies following platinum-based chemotherapy.
Common clinical features
Anterior mediastinal mass discovered incidentally on chest imaging or causing chest pain, dyspnoea, and superior vena cava syndromeMyasthenia gravis: fatigable muscle weakness, ptosis, diplopia, dysphagia, and respiratory compromisePure red cell aplasia presenting as severe, transfusion-dependent anaemiaHypogammaglobulinaemia (Good's syndrome) causing recurrent bacterial infectionsChest pain or phrenic nerve palsy from locally advanced diseasePleural or pericardial metastatic effusionDistant metastases to bone, liver, and extrathoracic lymph nodes in thymic carcinoma
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
11 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Sacituzumab Govitecan (Trodelvy)
Phase 2Pemetrexed Disodium (Alimta)
Phase 2Sunitinib (Sunitinib accord)
Phase 2Sacituzumab Tirumotecan
Phase 2Ivonescimab
Phase 2Erfonrilimab
Phase 2Avelumab (Bavencio)
Phase 2Belinostat (Beleodaq)
+ 3 more in development
Before you apply
Things trial teams commonly ask about for Thymoma and Thymic Carcinoma. Not eligibility rules; those are set by each study.
- WHO histological subtype (A/AB/B1/B2/B3 thymoma versus thymic carcinoma) is a key eligibility and stratification criterion — confirm the exact subtype is documented in the pathology report with expert review if necessary.
- Myasthenia gravis status and its treatment (acetylcholinesterase inhibitors, immunosuppressants, thymectomy history) must be disclosed as checkpoint inhibitors can precipitate severe myasthenic crisis and are often contraindicated or require close monitoring.
- Prior lines of platinum-based chemotherapy and recurrence status (resectable vs. unresectable/metastatic) determine eligibility for most second-line trials; provide a complete treatment chronology with response assessments.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).